Plain English Summary
Background and study aims
Acute pancreatitis (AP) is a sudden inflammation of the pancreas (an organ near the stomach that produces substances that aid digestion). AP is painful and can be life-threatening. It needs to be treated in hospital. This study aims to understand the lifestyle factors that increase or reduce the chance of developing AP. This knowledge could be used to suggest changes in lifestyle to help prevent AP in people who are at risk and to reduce the risk of AP or reduce its severity in people who have already had an episode of AP.
Who can participate?
1. People who have had AP in four groups relating to the possible cause of AP: gallstones, hypertriglyceridemia (high levels of fat in the blood), high alcohol intake, other (cystic fibrosis, injury, viral infection etc).
2. People who have not had AP but have one of the possible causes of AP: gallstones, hypertriglyceridemia (high levels of fat in the blood), high alcohol intake, other (cystic fibrosis, injury, viral infection etc).
3. People who are in hospital for reasons other than internal medicine disorders.
4. Healthy people who are not in hospital and have not had AP.
What does the study involve?
All participants will complete questionnaires about their socioeconomic factors (for example income level, social standing) and lifestyle (including dietary habits, physical activity, stress levels and sleep quality) covering the last year and the last month. The questionnaires will take about 2 hours to complete and trained administrators will help the participants to complete them.
What are the possible benefits and risks of participating?
There are no benefits and risks in participating in this study.
Where is the study run from?
The University of Pécs Medical School Institute for Translational Medicine (Hungary).
When is the study starting and how long is it expected to run for?
August 2018 to February 2024.
Who is funding the study?
The University of Pécs Medical School
Who is the main contact?
Erika Darvasi, co-principal investigator, Pancreatology Research Laboratory, 1st Department of Internal Medicine, University of Szeged.
szederke86@gmail.com
Trial website
Contact information
Type
Scientific
Primary contact
Prof Péter Hegyi
ORCID ID
http://orcid.org/0000-0003-0399-7259
Contact details
Szigeti str. 12.
Pécs
H-7624
Hungary
+36 72 536250
hegyi.peter@pte.hu
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
V1
Study information
Scientific title
LIFEStyle, Prevention and risk of Acute paNcreatitis (LIFESPAN): Protocol of a prospective, multicentre and multinational observational case-control study
Acronym
LIFESPAN
Study hypothesis
The main goal of our study is to determine negative or positive associations between socio-economic factors, dietary habits, physical activity, chronic stress and sleep quality and acute pancreatitis. This would enable us to suggest lifestyle modifications for patients discharged from the hospitals after AP or for those who wish to reduce their risk for AP.
Ethics approval
Secretary of Medical Research Council Scientific and Research Ethics Committee, 31/10/2018, ref: 54175-2/2018/EKU
Study design
Prospective observational multicentre case-control study.
Primary study design
Observational
Secondary study design
Case-control study
Trial setting
Hospitals
Trial type
Other
Patient information sheet
Not available in web format, please use contact details to request a participant information sheet.
Condition
Acute pancreatitis
Intervention
LIFESPAN is an observational study, therefore there is no intervention performed. Participants who fulfill the inclusion criteria will be asked to spend approximately 2 hours answering a complex questionnaire about their lifestyle and medical history. The questions cover eating and sleeping habits, physical activity, stress levels and socioeconomic status. We are going to ask the same questions concerning the last year and the last month. There is no follow-up in this study. The applied questionnaires are validated. Trained administrators will help the participants to complete them.
Every patient suffering from AP will have the opportunity to take part in the case group of the study. According to the etiology of the AP (alcoholic, biliary, hypertriglyceridemia or other), four subgroups will be formed. The four subgroups will be matched with the following control groups: (a) patients with alcoholic or biliary or hypertriglyceridemia background with no AP, (b) patients suffering from acute diseases other than internal medicine associated diseases and (c) healthy subjects.
Intervention type
Behavioural
Phase
Drug names
Primary outcome measure
1. Personal details and physical and socioeconomic status assessed using questions from the National Health and Nutrition Examination Survey (NHANES 2015-16), the American Community Survey (ACS) and the MacArthur Scale of Subjective Social Status.
2. Medical history assessed using the Acute Pancreatitis Questionnaire (Registry for Pancreatic Patients by Hungarian Pancreatic Study Group).
3. Dietary habits assessed using the Diet History Questionnaire, Version 2.0.
4. Physical activity assessed using the International Physical Activity Questionnaire (IPAQ, long, usual-week version) .
5. Stress levels assessed using the Perceived Stress Scale (10-item version).
6. Sleep quality assessed using the Pittsburgh Sleep Quality Index.
All these questionnaires were completed on the day of recruitment. Participants filled in two of each questionnaire - one covering the last year and one covering the last month.
7. Characteristics of acute AP assessed using the Acute Pancreatitis Questionnaire was filled out once by the AP participants only.
Secondary outcome measures
N/A
Overall trial start date
01/08/2018
Overall trial end date
28/02/2024
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
Patients with acute pancreatitis (AP):
1. Aged over 18 years
2. Diagnosed AP on the basis of the “2 out of 3” rules of the IAP/APA guideline: (a) upper abdominal pain; (b) serum amylase or lipase >3x upper limit of normal range; (c) characteristic findings on pancreatic imaging
3. Written informed consent form is signed.
Patients with AP in alcohol etiology group:
4. Patients consuming >5 drinks per day or >35 drinks per week for both sexes [= 8.75 units per day; 61.25 units per week] shall be included. Please note that 1 unit of alcohol = 10 ml or 8 g of pure (100%) alcohol.
Patients with AP in gallstone etiology group:
5. Presence of gallstone (not sludge).
Patients with AP in hypertriglyceridemia etiology group:
6. Triglyceride level in blood over 11 mmol/l.
Patients with AP in ‘other’ etiology group:
7. The causative agents do not match either of the first 3 groups, AP is induced by e.g.: endoscopic retrograde cholangiopancreatography (ERCP) (post-ERCP pancreatitis), virus infection, trauma, medicine (drug-induced pancreatitis), congenital anatomical malformation, cystic fibrosis, genetics, gluten sensitive enteropathy etc.
Control groups (Patients with no AP history):
8. Aged over 18 years
9. Absence of AP at present as well as in the medical history
10. Written informed consent form is signed
Control patients in alcohol group:
11. Patients consuming >5 drinks per day or >35 drinks per week for both sexes [= 8.75 units per day; 61.25 units per week] shall be included. Please note that 1 unit of alcohol = 10 ml or 8g of pure (100%) alcohol.
Control patients in gallstone group:
12. Presence of gallstone (not sludge).
Control patients in hypertrigliceridaemia group:
13. Triglyceride level over 11 mmol/l.
Control patients in hospital-based control group:
14. Hospital admissions in Traumatology, Ophthalmic Department, etc.
15. Control patients in population-based control group
Participant type
Mixed
Age group
Adult
Gender
Both
Target number of participants
3900, including 1700 patients in the AP group and 2200 subjects in the control groups
Participant exclusion criteria
1. Patients do not have reliable information or data.
2. Patients unlikely to adhere to study requirements.
Recruitment start date
01/04/2019
Recruitment end date
30/11/2023
Locations
Countries of recruitment
Hungary
Trial participating centre
University of Pécs, Medical School, Institute for Translational Medicine
Szigeti str. 12.
Pécs
H-7624
Hungary
Trial participating centre
University of Szeged, 1st Department of Medicine
Korányi fasor 8-10.
Szeged
H-6720
Hungary
Trial participating centre
University of Debrecen
Egyetem tér 1.
Debrecen
H-4032
Hungary
Trial participating centre
Fejér County Szent György Teaching Hospital
Seregélyesi str. 3.
Székesfehérvár
H-8000
Hungary
Sponsor information
Organisation
University of Pécs Medical School, Momentum Grant of the Hungarian Academy of Sciences
Sponsor details
LP2014-10/2014
Pécs
H-7624
Hungary
+36 72 536250
hegyi.peter@pte.hu
Sponsor type
University/education
Website
Organisation
Economic Development and Innovation Operative Programme Grant and Highly Cited Publication Grant of the National Research, Development and Innovation Office
Sponsor details
GINOP-2.3.2-15-2016-00048 'Stay Alive'
KH-125578 and EFOP 3.6.2-16-2017-00006 'Live Longer'
Pécs
H-7624
Hungary
+36 72 536250
hegyi.peter@pte.hu
Sponsor type
Government
Website
Organisation
Translational Medicine Foundation
Sponsor details
Pálfy str. 52/D
Szeged
H-6725
Hungary
+36 72 536250
hegyi.peter@pte.hu
Sponsor type
Hospital/treatment centre
Website
Organisation
Hungarian Academy of Sciences
Sponsor details
Sponsor type
Government
Website
Funders
Funder type
University/education
Funder name
Általános Orvostudományi Kar, Pécsi Tudományegyetem
Alternative name(s)
Medizinische Fakultät, Universität Pécs, PTE Általános Orvostudományi Kar, Medizinische Fakultät, Universität Pécs, Medical School, University of Pécs, ÁOK, PTE, UP MS, PTE ÁOK
Funding Body Type
government organisation
Funding Body Subtype
Local government
Location
Hungary
Results and Publications
Publication and dissemination plan
We plan to publish the results in a Q1 high-quality international journal.
IPD sharing statement:
The study data will be available upon request from the principal investigator (Prof. Péter Hegyi, Institute of Translational Medicine, University of Pécs, Medical School, hegyi.peter@pte.hu). The questionnaires, the eCFR (raw data) and the analyzed data can be available for other laboratories' reasonable use following a personal request.
Intention to publish date
30/06/2024
Participant level data
Available on request
Basic results (scientific)
Publication list